GSK (GSK) News Today

GSK plc (GSK) shares have risen on news of significant patent‐settlement payouts and promising clinical data.

• Positive Sentiment: GSK is set to collect $320 million as BioNTech and Pfizer settle their mRNA patent dispute with CureVac. GSK collects $320M as BioNTech, Pfizer settle mRNA patent spat with CureVac
• Positive Sentiment: GSK gains $370 million upfront plus reduced royalties under the same CureVac mRNA patent‐settlement agreement with Pfizer and BioNTech. GSK Gains $370 Million Upfront in CureVac mRNA Patent Settlement
• Positive Sentiment: Combined with CureVac’s share, GSK and CureVac stand to receive up to $740 million as the COVID-19 vaccine patent dispute is resolved. GSK, CureVac to receive $740M as COVID vaccine patent dispute settled
• Neutral Sentiment: GSK’s new study of GSK5764227 in gastrointestinal cancer shows early promise but remains in the investigational stage. GSK’s New Study on GSK5764227

Investors are responding positively to the influx of non-dilutive cash from patent settlements, which boosts GSK’s near-term liquidity and earnings visibility, while keeping an eye on the progress of the early‐stage cancer program.